Sfoglia per Autore
First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer
2006-01-01 Masi, G.; Marcucci, L.; Loupakis, F.; Cerri, E.; Barbara, C.; Bursi, S.; Allegrini, G.; Brunetti, I. M.; Murr, R.; Ricci, S.; Cupini, S.; Andreuccetti, M.; Falcone, Alfredo
Sequential treatment with cisplatin (P) in combination with infusional 5-FU/LV (PFL) followed by irinotecan (Ir) + 5-FU/LV (IrFL) followed by docetaxel (T) + 5-FU/LV (TFL) in patients (pts) with metastatic (M) gastric carcinoma (GC): Preliminary results of a phase II trial by the Gruppo Oncologico Nord-Ovest (G.O.N.O.)
2006-01-01 Loupakis, F.; Masi, G.; Fontana, E.; Picone, V.; Mentuccia, L.; Granetto, C.; Fea, E.; Pfanner, E.; Lencioni, M.; Falcone, Alfredo
Sequential treatment with cisplatin (P) in combination with infusional 5-FU/LV (PFL) followed by Irinotecan (IR) + 5-FU/LV (IRFL) followed by Docetaxel (T) + 5-FU/LV (TFL) in patients (PTS) with metastatic (M) gastric carcinoma (GC): preliminary results of a phase II trial by the Gruppo Oncologico Nord Ovest (G.O.N.O.)
2006-01-01 Loupakis, F.; Masi, G.; Fontana, E.; Allegrini, G.; Bursi, S.; Barbara, C.; Cerri, E.; Barletta, M. T.; Picone, V.; Mentuccia, L.; Granetto, C.; Fea, E.; Pfanner, E.; Murr, R.; Brunetti, I.; Andreuccetti, M.; Falcone, Alfredo
TREATMENT WITH 5FLUOROURACIL/FOLINIC ACID OXALIPLATIN AND IRINOTECAN ENABLES URGICAL RESECTION OF METASTASES IN PATIENTS WITH INITIALLY UNRESECTABLE METASTASTIC COLORECTAL CANCER
2006-01-01 Masi, G; Cupini, S; Marcucci, L; Cerri, E; Loupakis, F; Allegrini, G; Brunetti, Im; Pfanner, E; Viti, M; Goletti, Orlando; Filipponi, Franco; Falcone, Alfredo
Capecitabine and mitomycin C may be an effective treatment option for third-line chemotherapy in advanced colorectal cancer
2006-01-01 Scartozzi, M.; Falcone, Alfredo; Pucci, F.; Barconi, C.; Pierantoni, C.; Capanna, L.; Franciosi, V.; Berardi, R.; Beretta, G.; Masi, G.; Allegrini, G.; Zaniboni, A.; Labianca, R.; Cascinu, S.
Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation
2006-01-01 Allegrini, G; DI PAOLO, Antonello; Cerri, E; Cupini, S; Amatori, F; Masi, G; Danesi, Romano; Marcucci, L; Bocci, Guido; DEL TACCA, M; Falcone, Alfredo
Long-term outcome of unresectable metastatic colorectal cancer (MCRC) patients (pts) treated with first-line FOLFOXIRI followed by R0 surgical resection of metastases
2007-01-01 Masi, G.; Bursi, S.; Loupakis, F.; Barbara, C.; Brunetti, I.; Ferraldeschi, R.; Evangelista, W.; Chiara, S.; Granetto, C.; Falcone, Alfredo
First line treatment of metastatic colorectal cancer (MCRC) with the combination of capecitabine, irinotecan, and oxaliplatin (XELOXIRI): Preliminary results of a pilot study by the G.O.N.O. Group
2007-01-01 Bursi, S.; Masi, G.; Loupakis, F.; Antonuzzo, A.; Tognarini, L.; Sonaglio, C.; Chiara, S.; Pfanner, E.; Brunetti, I.; Petrini, Iacopo; Baldi, G.; Barletta, M.; Allegrini, G.; Ricci, S.; Falcone, Alfredo
The combination of capecitabine (C), irinotecan (I) and oxaliplatin (O) (XELOXIRI) as first line treatment of metastatic colorectal cancer (MCRC): Preliminary results of a pilot study by the Gruppo Oncologico Nord-Ovest (G.O.N.O.)
2007-01-01 Masi, G.; Bursi, S.; Loupakis, F.; Barletta, M.; Baldi, G.; Antonuzzo, A.; Sonaglio, C.; Pfanner, E.; Petrini, Iacopo; Falcone, Alfredo
Sequential chemotherapy with capecitabine and irinotecan followed by capecitabine and oxaliplatin in elderly vulnerable patients (pts) with metastatic colorectal cancer (MCRC)
2007-01-01 Cupini, S.; Bursi, S.; Masi, G.; Loupakis, F.; Barbara, C.; Barletta, M. T.; Baldi, G. G.; Vasile, E.; Fornaro, L.; Petrini, Iacopo; Allegrini, G.; Antonuzzo, A.; DI MARSICO, R.; Andreuccetti, M.; Ricci, S.; Falcone, Alfredo
First-line folfoxiri followed by R0 surgical resection of metastases in unresectable metastatic colorectal cancer (MCRC) patients (pts)
2007-01-01 Masi, G.; Loupakis, F.; Bursi, S.; Barbara, C.; Barletta, M. T.; Baldi, G.; Cupini, S.; Brunetti, I.; Pfanner, E.; Lencioni, M.; DI DONATO, S.; Mentuccia, L.; Fanchini, L.; Sonaglio, C.; Fea, E.; Allegrini, G.; Falcone, Alfredo
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy
2007-01-01 Ruzzo, Annamaria; Graziano, Francesco; Loupakis, Fotios; Rulli, Eliana; Canestrari, Emanuele; Santini, Daniele; Catalano, Vincenzo; Ficarelli, Rita; Maltese, Paolo; Bisonni, Renato; Masi, Gianluca; Schiavon, Gaia; Giordani, Paolo; Giustini, Lucio; Falcone, Alfredo; Tonini, Giuseppe; Silva, Rosarita; Mattioli, Rodolfo; Floriani, Irene; Magnani, Mauro
Updated results, multivariate and subgroups analysis confirm improved activity and efficacy for FOLFOXIRI versus FOLFIRI in the G.O.N.O. randomized phase III study in metastatic colorectal cancer (MCRC)
2007-01-01 Falcone, Alfredo; Andreuccetti, M.; Brunetti, I.; Ricci, S.; Barbara, C.; Evangelista, W.; Passeri, V.; Chiara, S.; Allegrini, G.; Masi, G.
Phase II study of sequential chemotherapy with cisplatin (P) in combination with infusional 5FU/LV (PFL) followed by irinotecan (IR) + 5FU/LV (IrFL) followed by docetaxel (T) + 5FU/LV (TFL) in patients (pts) with metastatic gastric carcinoma (MGC) by the Gruppo Oncologico Nord-Ovest (GONO)
2007-01-01 Loupakis, F.; Masi, G.; Bursi, S.; Picone, V.; Mentuccia, L.; Granetto, C.; Fea, E.; Murr, R.; Antonuzzo, A.; Falcone, Alfredo
Randomized phase III study of FOLFOXIRI (irinotecan, oxaliplatin and infusional 5FU/LV) vs FOLFIRI (irinotecan and 5FU/LV) as first-line treatment of metastatic colorectal cancer (MCRC): Subgroup and multivariate analysis
2007-01-01 Falcone, Alfredo; Andreuccetti, M.; Orlandini, C.; Barbara, C.; Benedetti, G.; Evangelista, W.; Picone, V.; Chiara, S.; Granetto, C.; Masi, G.
Folfoxiri compared to Folfiri as first-line treatment of metastatic colorectal cancer(MCRC): Updated results, multivariate and subgroups analisys of the G.O.N.O. randomized phase III study
2007-01-01 Falcone, Alfredo; Andreuccetti, M.; Ricci, S.; Orlandini, C.; Barbara, C.; Evangelista, W.; Ciuffreda, L.; Cortesi, E.; Ferraldeschi, R.; Chiara, S.; Granetto, C.; Loupakis, F.; Bursi, S.; Allegrini, G.; Masi, G.
Vascular endothelial growth factor levels in immunodepleted plasma of cancer patients as a possible pharmacodynamic marker for bevacizumab activity.
2007-01-01 Loupakis, F.; Falcone, Alfredo; Masi, G.; Fioravanti, Anna; Kerbel, R. S.; Del Tacca, M.; Bocci, Guido
Long-term outcome of unresectable metastatic colorectal cancer (MCRC) patients (pts) treated with first-line folfoxiri followed by r0 surgical resection of metastases
2007-01-01 Masi, G.; Bursi, S.; Loupakis, F.; Barletta, M.; Barbara, C.; Vasile, E.; Cupini, S.; Brunetti, I.; Pfanner, E.; DI DONATO, S.; Dauria, G.; Fanchini, L.; Chiara, S.; Granetto, C.; Falcone, Alfredo
Capecitabine ( C ), in combination with irinotecan ( I ) and oxaliplatin ( O ) (XELOXIRI) as first-line treatment of metastatic colorectal cancer (MCRC): results of a pilot study by the Gruppo Oncologico Nord-Ovest (G.O.N.O.)
2007-01-01 Bursi, S.; Masi, G.; Loupakis, F.; Antonuzzo, A.; Chiara, S.; Pfanner, E.; Petrini, Iacopo; Barletta, M. T.; Baldi, G. G.; Falcone, Alfredo
Metronomic chemotherapy (MC) with irinotecan (CPT-11) in patients with diagnosis of metastatic colorectal cancer (MCRC): clinical, pharmacodynamic (PD) and pharmacokinetic (PK) evaluation. Final report
2007-01-01 Barletta, M. T.; Bocci, Guido; Loupakis, F.; Fioravanti, A.; Baldi, G.; Orlandi, P.; Allegrini, G.; Masi, G.; Barbara, C.; Andreuccetti, M.; Cupini, S.; Bursi, S.; Danesi, Romano; DI PAOLO, Antonello; DEL TACCA, M.; Falcone, Alfredo
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile